Illumina has completed its acquisition of SomaLogic, a leader in data-driven proteomics technology, for $350 million in cash plus up to $75 million in performance-based milestones and royalties. The move expands Illumina’s capabilities in proteomics and multiomics, integrating SomaLogic’s SomaScan Proteomics Assay with Illumina’s next-generation sequencing ecosystem and DRAGEN software. Illumina will continue supporting SomaLogic’s existing customers and service providers as it incorporates SomaLogic’s portfolio into its product and solutions roadmap. The financial details of the transaction will be discussed in Illumina’s upcoming earnings call.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Illumina Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA74934) on January 30, 2026, and is solely responsible for the information contained therein.